Allopurinol Treatment to Protect Brain and Heart in Newborns with Critical Congenital Heart Disease Undergoing Cardiac Surgery with Cardiopulmonary Bypass
Led by dr. M.J.N.L. Benders · Updated on 2024-05-16
236
Participants Needed
4
Research Sites
113 weeks
Total Duration
AI-Summary
What This Trial Is About
Neurodevelopmental problems caused by delayed brain development and brain injury are common in children with critical congenital heart disease CCHD. These children often face long-term motor, cognitive, and behavioral challenges due to brain injury occurring early after birth and around the time of heart surgery. Researchers are studying whether the drug allopurinol, which reduces harmful oxygen radicals, can protect the brain and heart in these children during this vulnerable period.
The study compares allopurinol with a placebo in newborns diagnosed with CCHD who need heart surgery using cardiopulmonary bypass within their first month of life. Allopurinol or placebo is given multiple times early after birth, before surgery, during surgery, and after surgery, depending on when the diagnosis is made. The goal is to see if allopurinol can reduce brain injury and protect heart function during these critical times.
Participants will undergo brain MRI scans before and after surgery to assess brain injury, as well as monitoring of brain function and oxygen levels at specific times around birth and surgery. Researchers will also evaluate motor skills and neurodevelopment at 3 months and 24 months of age. The study tracks outcomes including brain injury severity, heart function, seizures, quality of life, and mortality up to one month after surgery. This comprehensive monitoring aims to understand allopurinols effects on brain and heart health in these newborns.
CONDITIONS
Brief Title
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Research Team
M
Manon JNL Benders, Prof. MD PhD
M
Maaike Nijman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborating Sponsor
Who Can Participate
Age: 0 - 1Month
All Genders
Eligibility Criteria
You may qualify if you...
Neonates with a confirmed diagnosis of critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass within the first 4 weeks of life
Informed consent provided by both parents
You will not qualify if you...
Unable to enroll before delivery for prenatal diagnosis or within 24 hours before surgery for postnatal diagnosis
Uncertainty if aortic arch anomaly requires cardiac surgery with cardiopulmonary bypass in the neonatal period
Gestational age below 36 weeks and/or birth weight less than 2000 grams
Surgery not requiring cardiopulmonary bypass
Decision for comfort care only
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Treatment
Duration - From birth until 24 hours after surgery
Participants receive allopurinol or placebo at multiple time points including early postnatal, preoperative, intraoperative, and postoperative periods around cardiac surgery.
Multiple visits around surgery including early postnatal, preoperative, intraoperative, and postoperative administration
Follow-up
Duration - Up to 24 months after surgery
Participants undergo postoperative monitoring including MRI scans, brain function assessments, and neurodevelopmental evaluations.
Visits for MRI and brain assessments within 1 month after surgery; additional visits at 3 months and 24 months for neurodevelopment and quality of life evaluations
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of sST2 Blood Marker to Predict Heart Failure in Children Undergoing Congenital Heart Surgery
Allopurinol Treatment to Protect Brain and Heart in Newborns with Critical Congenital Heart Disease Undergoing Cardiac Surgery with Cardiopulmonary Bypass
Comparing Continuous Infusion and Intermittent Ketorolac for Pain Relief After Pediatric Heart Surgery in Children Aged 3 Months to 5 Years
Study of BrudyGlauco DHA and Citicoline to Protect Vision in Adults with Glaucoma
Randomized, Double-Blind, Placebo-Controlled Trial Lasting 12 Months
Screening Neurodevelopmental Disorders by Advanced Practice Nurse in Children Aged 1 to 5 with Congenital Heart Disease
Safety and Feasibility of Intra-Arterial 3-n-Butylphthalide for Acute Ischemic Stroke Patients Without Reperfusion Therapy
Study of Outcomes and Health Care Use in Children and Young Adults with Congenital Heart Disease Having Non-Heart Procedures
Remote Cardiac Rehabilitation Using Video Coaching for Teens with Congenital Heart Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease.
CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial.
Raymond Stegeman, Maaike Nijman, Johannes M P J Breur...